

IN THE CLAIMS

1. (Currently Amended) A method for treating premature ejaculation in patients with normal erectile function comprising orally administering a an effective amount of a PDE5 inhibitor without co-administration of an estrogen agonist/antagonist.
2. (Original) The method according to claim 1 wherein the inhibitor is sildenafil.
3. (Original) The method according to either claim 1 wherein the PDE5 inhibitor has an IC₅₀ against the PDE5 enzyme of less than 100 nanomolar.
4. (Original) The method according to claim 3 wherein the PDE5 inhibitor has a selectivity over PDE3 of greater than 100 fold.
5. (Original) The method according to claim 4 wherein the PDE5 inhibitor has a selectivity over both PDE3 and PDE4 of greater than 100 fold.
6. (Original) The method according to claim 5 wherein the PDE5 inhibitor has an IC₅₀ against PDE5 of less than 100 nM and a selectivity over PDE3 of greater than 100 fold.
7. (Original) The method according to claim 1 wherein the PDE5 inhibitor is selected from the group:
5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (sildenafil);
(6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl) -pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione (IC-351);

2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-
3H-imidazo[5,1-f][1,2,4]triazin-4-one (vardenafil);
5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-[2-
methoxyethyl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; and
5-(5-acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidinyl)-2,6-dihydro-
7H-pyrazolo[4,3-d]pyrimidin-7-one and pharmaceutically acceptable salts
thereof.

8. Cancelled.

9. (Original) The method according to claim 8 wherein the daily dosage is 5
to 500 mg.

10. (Original) The method according to claim 9 wherein the daily dosage is
10 to 100 mg.

11. Cancelled.

A
Concl'd